1. 31P Development of a biomarker-based calculator to predict the probability to achieve a pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. (15th December 2019) Authors: Marandino, L; Bandini, M; Madison, R; Raggi, D; Gallina, A; Colecchia, M; Lucianò, R; Giannatempo, P; Farè, E; Pederzoli, F; Bianchi, M; Colombo, R; Capitanio, U; Ali, S M; Chung, J H; Ross, J; Salonia, A; Briganti, A; Montorsi, F; Necchi, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 11 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 866PDComprehensive biomarker analyses and updated results of PURE-01 study: Neoadjuvant pembrolizumab (pembro) in muscle-invasive urothelial bladder carcinoma (MIBC). (23rd October 2018) Authors: Necchi, A; Briganti, A; Raggi, D; Luciano, R; Colecchia, M; Massa, S; Giannatempo, P; Colombo, R; Gallina, A; Salvioni, R; Mortarini, R; Montorsi, F; Madison, R; Ali, S M; Ross, J S; Chung, J; Anichini, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. Issue 5 (May 1997) Authors: Colecchia, M; Frigo, B; Del Boca, C; Guardamagna, A; Zucchi, A; Colloi, D; Leopardi, O Journal: Journal of clinical pathology Issue: Volume 50:Issue 5(1997) Page Start: 384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗